Circassia Group plc
Block Listing Interim Review
Oxford, UK - 31 March 2021: Circassia Group plc ("Circassia" or "the Company") (LSE: CIR), a medical device company focused on respiratory diagnostics and monitoring, makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:
| Name of the company: | Circassia Group plc | |||
| Name of relevant scheme: | 1) Circassia EMI Share Option Scheme 2) Circassia 2007 Unapproved Share Scheme 3) Circassia 2014 Performance Share Plan Scheme 4) Circassia 2015 Performance Share Plan Scheme 5) Circassia 2016 Performance Share Plan Scheme 6) Circassia 2017 Performance Share Plan Scheme | |||
| Period of return: | From: | 1 October 2020 | To: | 31 March 2021 |
| Balance of unallotted securities under scheme(s) from previous return: | 1) 700,750 2) 203,000 3) 76,676 4) 251,864 5) 739,905 6) 678,980 Total: 2,651,175 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 1) - 6) inclusive: Nil | |||
| Less: Number of securities issued/allotted under scheme(s) during period: | 1) - 3) inclusive: Nil 4) (13,845) 5) (30,362) 6) (281,684) Total: (325,891) | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 1) 700,750 2) 203,000 3) 76,676 4) 238,019 5) 709,543 6) 397,296 Total: 2,325,284 | |||
| Number and class of securities originally listed and the date of admission: | 1) 2,600,000 - 20 March 2014 2) 516,000 - 1 June 2017 3) 500,000 - 1 June 2017 4) 400,000 - 21 May 2018 5) 930,000 - 1 July 2019 6) 980,000 - 22 May 2020 | |||
For further information, please contact:
| Circassia Sarah Duncan, Company Secretary
| Tel: +44(0)1865 405566 |
| N+1 Singer (Nominated Adviser and Broker) Aubrey Powell / Jen Boorer / Hannah Woodley
| Tel: +44 (0) 20 7496 3000 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
